Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk.

The 2018 American Heart Association/American College of Cardiology/Multi-Society (AHA/ACC/MS) Guideline on the Management of Blood Cholesterol and the 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines for the Management of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk, that were recently released by the United States and Europe, provide new recommendations for the management of blood lipid levels based on the latest evidence. Despite many common points, there are several differences in the recommendations, including the definition of very-high-risk patient category, the recommendations for some categories of patients, such as those with diabetes, familial hypercholesterolemia, chronic kidney disease, and aged patients, and the use of ezetimibe and PCSK9 inhibitors. These differences suggest that multiple approaches can be used to manage lipid abnormalities in the context of cardiovascular risk reduction.
Competing Interests: Declaration of competing interest LT has received consulting fees/honoraria from Abbott, Amgen, Bayer, Daiichi-Sankyo, Jansen, MSD, Mylan, NovoNordisk, Pfizer, Recordati, Sanofi, Servier; MC and AP have nothing to disclose; ALC reports grants from Amgen, Sanofi, Regeneron personal fees from Merck, Sanofi, Regeneron, AstraZeneca, Amgen, Novartis, outside the submitted work.
(Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)